We provide a detailed protocol for a ubiquitylation assay of a specific substrate and an E3 ubiquitin-ligase in mammalian cells. HEK293T cell lines were used for protein overexpression, the polyubiquitylated substrate was purified from cell lysates by immunoprecipitation, and resolved in SDS-PAGE. Immunoblotting was used to visualize this post-translational modification.
Ubiquitylation is a post-translational modification which occurs in eukaryotic cells that is critical for several biological pathways’ regulation, including cell survival, proliferation, and differentiation. It is a reversible process that consists of a covalent attachment of ubiquitin to the substrate through a cascade reaction of at least three different enzymes, composed of E1 (Ubiquitin-activation enzyme), E2 (Ubiquitin-conjugating enzyme), and E3 (Ubiquitin-ligase enzyme). The E3 complex plays an important role in substrate recognition and ubiquitylation. Here, a protocol is described to evaluate substrate ubiquitylation in mammalian cells using transient co-transfection of a plasmid encoding the selected substrate, an E3 ubiquitin ligase, and a tagged ubiquitin. Before lysis, the transfected cells are treated with the proteasome inhibitor MG132 (carbobenzoxy-leu-leu-leucinal) to avoid substrate proteasomal degradation. Furthermore, the cell extract is submitted to small-scale immunoprecipitation (IP) to purify the polyubiquitylated substrate for subsequent detection by western blotting (WB) using specific antibodies for ubiquitin tag. Hence, a consistent and uncomplicated protocol for ubiquitylation assay in mammalian cells is described to assist scientists in addressing ubiquitylation of specific substrates and E3 ubiquitin ligases.
Post-translational modifications (PTMs) are an important mechanism regarding protein regulation, which is essential for cell homeostasis. Protein ubiquitylation is a dynamic and intricate modification that creates an assortment of different signals resulting in several cellular outcomes in eukaryotic organisms. Ubiquitylation is a reversible process consisting in the attachment of a ubiquitin protein containing 76 amino acids to the substrate, occurring in an enzymatic cascade composed by three distinct reactions1. The first step is characterized by ubiquitin activation, which depends on an ATP hydrolysis to form a high-energy thioester-linked ubiquitin between the ubiquitin C-terminus and the cysteine residue present in the active site of the E1 enzyme. Subsequently, the ubiquitin is transferred to the E2 enzyme forming a thioester-liked complex with the ubiquitin. Afterward, the ubiquitin is covalently attached to the substrate by the E2, or more often, by the E3 enzyme, which recognizes and interacts with the substrate2,3. Occasionally, E4 enzymes (Ubiquitin-chain elongation factors) are necessary to promote multiubiquitin chain assembly3.
Ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, K48, and K63), allowing the formation of polyubiquitin chains that generate distinct linkages to produce different tridimensional structures that are going to be recognized by several effector proteins4,5. Hence, the kind of polyubiquitin chain introduced in the substrate is essential to decide its cell fate6,7,8. Moreover, the substrate could also be ubiquitinated through its N-terminal residues called N-degrons. Specific E3 ubiquitin-ligases are responsible for N-degron recognition, allowing the polyubiquitylation of nearby lysine residue9.
Nowadays, there are more than 40 different SCF-specific substrates characterized. Among those, key regulators of several biological pathways, including cell differentiation and development as well as cell survival and death, can be found10,11,12,13. Thus, the identification of specific substrates of each E3 ubiquitin-ligase is essential to design a comprehensive map of various biological events. Even though the identification of true substrates is biochemically challenging, the use of biochemistry-based methods is very suitable to evaluate chain specificity and the distinction between mono- and polyubiquitylation14. This study describes a complete protocol for ubiquitylation assay using the mammalian cell line HEK293T overexpressing the substrate UXT-V2 (Ubiquitously expressed prefoldin-like chaperone isoform 2) with the E3 ubiquitin-ligase complex SCF(Fbxo7). UXT-V2 is an essential co-factor for NF-κB signaling, and once this protein is knocked down in cells, it inhibits TNF-α-induced NF-κB activation11. Thus, to detect polyubiquitylated UXT-V2, the proteasome inhibitor MG132 is used since it has the ability to block the proteolytic activity of the 26S subunit of the proteasome complex15. Furthermore, the cell extract is submitted to a small-scale IP to purify the substrate, utilizing a specific antibody immobilized to agarose resin for subsequent detection by WB using selected antibodies. This protocol is very useful to validate substrate ubiquitylation in the cellular environment, and it can also be adapted for different types of mammalian cells and other E3 ubiquitin-ligase complexes. However, it is necessary to validate the substrate tested through an in vitro ubiquitylation assay as well, since both protocols complement each other regarding the identification of true substrates.
NOTE: An overview of ubiquitylation assay protocol in mammalian cells is represented in Figure 1.
Figure 1. Overview of the ubiquitylation assay procedure. Please click here to view a larger version of this figure.
1. Cell culture
2. Cell transfection
NOTE: It is not recommended to transfect the cell culture if the confluence reached is less than 80%.
3. Cell lysis and immunoprecipitation
UXT (ubiquitously expressed transcript) is a prefoldin-like protein that forms ubiquitously expressed protein-folding complexes in mouse and human tissues such as heart, brain, skeletal muscle, placenta, pancreas, kidney, and liver18. Two splicing isoforms of UXT, which are named UXT-V1 and UXT-V2, have been described performing distinct functions and subcellular locations. UXT-V1 is predominantly localized in the cytoplasm and inside the mitochondria, and it is implicated in TNF-α-induced apoptosis and antiviral signalosome formation19,20. Most research has focused on UXT-V2 that is mainly localized in the nucleus and acts as a co-factor for multiple transcriptional factors involved in cell proliferation regulation, differentiation, and in inflammatory pathways. UXT-V2 is involved in the NF-κB signaling pathway working as an essential coactivator in the NF-κB enhanceosome21. It was demonstrated that UXT-V2 is a canonical substrate of the E3 ubiquitin-ligase SCF(Fbxo7), mediating its polyubiquitylation and degradation by the proteasome, and consequently inhibiting the NF-κB signaling pathway11.
The specific polyubiquitylation of UXT-V2-HA mediated by Fbxo7 in cells was observed after probing the eluate from anti-HA IP with an anti-myc antibody, which detects the myc-ub conjugated to the substrate (Figure 2). The specificity of anti-myc for polyubiquitylated substrate was visualized in lanes 1 and 2 (Figure 2), wherein smear of polyubiquitylated proteins was not detected when cells were co-transfected with Fbxo7 and myc-ub in the absence of UXT-V2-HA plasmid (Figure 2, lane 1). Additionally, no smear corresponding to protein polyubiquitination was visualized in the combination of Fbxo7 and UXT-V2-HA without the myc-ub plasmid (Figure 2, lane 2). To prove that UXT-V2 polyubiquitylation was mediated by Fbxo7, an empty vector pcDNA3, wild type Fbxo7 or Fbxo7-ΔF-box mutant, which is unable to assemble active SCF complex due to the absence of the F-box domain that is responsible for interaction with SKP1, was transfected in combination with UXT-V2-HA and myc-ub. A strong smear signal of polyubiquitylated UXT-V2 was observed only in the presence of the wild-type Fbxo7 (Figure 2, lane 4), suggesting that UXT-V2 was polyubiquitylated by SCF(Fbxo7) complex in cells compared to the controls (Figure 2, lanes 3 and 5). The presence of a faint smear signal of polyubiquitylated UXT-V2 in the presence of these negative controls might indicate the action of endogenous Fbxo7 or other E3 ubiquitin-ligase activity.
Figure 2. Ubiquitylation assay in cells: Transient transfection of HEK293T cells with the indicated plasmids. After cell lysis, the cell extracts (inputs) were immunoprecipitated with agarose-anti-HA beads. The eluted and input samples were resolved by SDS-PAGE, and the western blot was probed with specific antibodies. Please click here to view a larger version of this figure.
Ubiquitylation is an essential post-translational modification that regulates the levels of several proteins and plays a crucial role in many signaling pathways and biological processes, ensuring a healthy intracellular environment. The ubiquitin-proteasome system (UPS) is one of the main focuses of recent pharmaceutical research, providing the possibility of stabilizing tumor suppressors or inducing the degradation of oncogenic products22. For instance, the aberrant proliferation of plasma cell neoplasms responsible for monoclonal immunoglobulin secretion in multiple myeloma (MM) promotes a pathophysiological pathway due to misfolded and/or unfolded protein accumulation in the endoplasmic reticulum (ER)23. Once this ER stress happens, it activates several processes, including the activation of the ubiquitin-proteasome system. The use of proteasome inhibitors (bortezomib, carfilzomib, and ixazomib) to induce protein accumulation and consequent cell death for multiple myeloma treatment showed promising results as an anti-tumor drug by reducing disease progression in high-risk patients24,25. Moreover, other efforts focused on protein stability are aimed, such as inhibitors for the E3 ubiquitin-ligase MDM2 that showed great ability in avoiding the ubiquitylation of p53, hence preventing its degradation through the proteasome26. Thus, a new era of pharmaceutical/biomedical research centered on understanding and controlling the UPS as a method to combat the disease has arisen.
This study describes a method to analyze the ubiquitylation of a specific target protein by a given E3 ubiquitin-ligase in a cellular environment. In this assay, a significant number of cells are transiently co-transfected with selected plasmids encoding for a tagged protein substrate, an E3 ligase, and a tagged ubiquitin. Before lysis, the cells must be treated with a proteasome inhibitor to allow the accumulation of polyubiquitylated proteins that would undergo degradation in the proteasome. In order to obtain a less complex sample, the target protein was immunoprecipitated, and its polyubiquitylation was analyzed by WB using specific antibodies based on the ubiquitin tag.
The amount of protein in each sample and agarose beads must be normalized to allow the data comparison among those samples. A high-intensity smear signal of UXT-V2 polyubiquitylation in the presence of the wild-type E3 ubiquitin-ligase was detected. Even though the signal obtained from the target protein, the E3 ligase, and the ubiquitin could be from an endogenous origin, the use of recombinant proteins has the advantage of higher yield and signal detection in WB analysis. Furthermore, using the wild-type E3 ligase and its mutant allows the specific analysis of their activity in the substrate, which is an essential control for this experiment. It was observed that the Fbxo7 mutant (Fbxo7-ΔF-box) could not promote the polyubiquitylation of UXT-V2, suggesting the smear signal detected in the presence of the wild-type Fbxo7 was specific. In addition, it is important to observe that in the absence of the tagged substrate or myc-ub, the polyubiquitylated smear was not detected, indicating the specificity of agarose-anti-HA used. Using an anti-ubiquitin antibody to probe the eluate from substrate IP might detect a polyubiquitylated smear signal even in the negative controls, since unspecific proteins or indirect protein partners of the target can also be eluted together with the substrate. Once these unspecific proteins might be polyubiquitylated, the high sensitivity of anti-ubiquitin can detect them.
There are also some variations for this protocol regarding plasmid transfection, cell lysis buffer, immunoprecipitation antibody, and WB probing. The IP presented here was developed with anti-HA antibody to precipitate the substrate, and the WB membrane was probed with anti-myc antibody to visualize the ubiquitin signal. The transfection of ubiquitin-HA and IP with anti-HA and WB probing the membrane with an anti-substrate or anti-substrate tag is also an alternative for this methodology. However, the immunoprecipitation of ubiquitin might bring a huge number of unspecific polyubiquitylated proteins in addition to ubiquitin-binding proteins. In this case, it is recommended to use RIPA buffer (radioimmunoprecipitation assay buffer) during cell lysis to minimize these undesired proteins27. However, it is essential to evaluate whether the IP protocol is compatible with RIPA buffer. Furthermore, substrate polyubiquitylation might impair the binding of the antibody to this specific target by blocking the conformational epitope. Thus, the application of antibodies with anti- tag is more reliable.
While this approach is very useful for soluble protein purification, it presents some limitations. First, the action of unspecific endogenous E3 ubiquitin-ligases could be observed. To overcome this issue and to confirm the specificity of the target ubiquitylation in cells, it is essential to also perform an in vitro ubiquitylation assay using purified E3 ligase complex and selected substrate in addition to E1 and E2 enzymes, ubiquitin, ubiquitin buffer, and ATP, which are commercially available. Another limitation of this method occurs when the overexpression of the target protein causes a cytotoxic effect that culminates in reduced cellular viability. In this situation, using the endogenous protein target for immunoprecipitation is recommended. Additionally, as mentioned above, this protocol is suitable for soluble protein extraction; therefore, it cannot extract membrane-bound proteins, for instance. Whether the substrate tested is a membrane protein, the RIPA buffer could replace the NP-40 lysis buffer described here if the IP protocol is not compromised by it. In this protocol, the focus of protein clearance is the ubiquitin-proteasome system, which explains that only the proteasome inhibitor was used. However, numerous soluble proteins undergo degradation through autophagy in the lysosome. Consequently, using a lysosome inhibitor, such as bafilomycin A1, could also be necessary to block late-phase autophagy due to vacuolar H+-ATPase28.
Since ubiquitylation is a reversible process, the ubiquitin can be removed from the substrate by the catalytic activity of deubiquitinases (DUBs); this is one of the major obstacles when characterizing E3 ubiquitin-ligase substrates29. The action of DUBs increases the substrate discrimination in this kind of experiment once it decreases polyubiquitylation dwell times on some targets30. Therefore, it would be beneficial to treat the cells with deubiquitinase inhibitors to avoid this problem. Positive or negative crosstalk could also influence the fate of a specific substrate. It is already established that post-translational modifications (PTMs) can crosstalk in various scenarios, and phosphorylation, for example, can regulate ubiquitylation by modulation of E3 ubiquitin-ligase activity, promoting substrate recognition by E3 ligases or through regulating substrate and E3 ligase interaction by affecting its cellular localization31. This could be an issue when choosing the cell line in which the experiment will be executed. If the signals that are prerequisites for ubiquitylation are absent in the desirable cell line, it is required to select an alternative cell line to conduct the analysis or induce the signal in the cell line selected. A common problem that may occur in ubiquitylation assays performed in cells is massive cell death after MG132 treatment, which is mostly caused by the generation of reactive oxygen species (ROS) that induce apoptotic cell death. After several tests to standardize the protocol, it was found an ideal MG132 treatment for HEK293T cells to not exceed 6 h before lysis at 10 µM of concentration. This protocol is also suitable for other mammalian cell types to identify substrate-E3 ubiquitin-ligase pairs; although, it is crucial to standardize the volume of PEI used in the transfection and the MG132 treatment period for the chosen cell line.
The authors have nothing to disclose.
F.R.T is supported by FAPESP grant number 2020/15771-6 and CNPq Universal 405836/2018-0. P.M.S.P and V.S are supported by CAPES. C.R.S.T.B.C was supported by FAPESP scholarship number 2019/23466-1. We thank Sandra R. C. Maruyama (FAPESP 2016/20258-0) for the material support.
1.5 mL microtube | Axygen | PMI110-06A | |
100 mm TC-treated culture dish | Corning | 430167 | |
15 mL tube | Corning | 430766 | |
96-well plate | Cralplast | 655111 | |
Agarose-anti-HA beads | Sigma-Aldrich | E6779 | |
Anti Mouse antibody | Seracare | 5220-0341 | Goat anti-Mouse IgG |
Anti Rabbit antibody | Seracare | 5220-0337 | Goat anti-Rabbit IgG |
Anti-Actin antibody | Sigma-Aldrich | A3853 | Dilution used: 1:2000 |
Anti-Fbxo7 antibody | Sigma-Aldrich | SAB1407251 | Dilution used: 1:1000 |
Anti-HA antibody | Sigma-Aldrich | H3663 | Dilution used: 1:1000 |
Anti-Myc antibody | Cell Signalling | 2272 | Dilution used: 1:1000 |
Bradford reagent | Sigma-Aldrich | B6916-500ML | |
BSA | Sigma-Aldrich | A9647-100G | Bovine Serum Albumin |
Cell incubator | Nuaire | NU-4850 | |
Centrifuge | Eppendorf | 5804R | 500 x g for 5 min |
ChemiDoc | BioRad | ||
Digital pH meter | Kasvi | K39-2014B | |
Dulbecco’s Modified Eagle’s Medium | Corning | 10-017-CRV | High glucose |
Fetal bovine serum | Gibco | F4135 | Filtrate prior use |
HA peptide | Sigma-Aldrich | I2149 | |
HEK293T cells | ATCC | CRL-3216 | |
Hepes | Gibco | 15630080 | |
KCl | VWR Life Science | 0365-500G | |
Kline rotator | Global Trade Technology | GT-2OIBD | |
MG-132 | Boston Biochem | I-130 | |
Microcentrifuge | Eppendorf | 5418R | |
Na3VO4 (Ortovanadato) | |||
NaF | |||
Nitrocellulose blotting membrane | GE Healthcare | 10600016 | |
NP40 (IGEPAL CA-630) | Sigma-Aldrich | I8896-100ML | |
Optical microscope | OPTIKA microscopes | SN510768 | |
Opti-MEM | Gibco | 31985-070 | |
pcDNA3 | Invitrogen | V79020 | For mammalian expression |
pcDNA3-2xFlag-Fbxo7 | Kindly donated by Dr. Marcelo Damário | Tag 2xFlag (N-terminal). Restriction enzymes: EcoRI and XhoI | |
pcDNA3-2xFlag-Fbxo7-ΔF-box | Kindly donated by Dr. Marcelo Damário | Tag 2xFlag (N-terminal). Restriction enzymes: EcoRI and XhoI. Δ335-367 | |
pcDNA3-UXTV2-HA | Kindly donated by Dr. Marcelo Damário | Tag HA (C-terminal). Restriction enzymes: EcoRI and XhoI | |
pCMV-6xHis-Myc-Ubiquitin | Kindly donated by Dr. Marcelo Damário | Tag 6x-His-Myc (N-terminal). Restriction enzymes: EcoRI and KpnI | |
Pen Strep Glutamine 100x | Gibco | 10378-016 | |
Phosphate buffered saline 10x | AccuGENE | 51226 | To obtain a 1x PBS, dilute the 10x PBS into ultrapure water |
Polyethylenimine (PEI) | Sigma-Aldrich | 9002-98-6 | |
Ponceau S | VWR Life Science | 0860-50G | |
Protease inhibitor cocktail SIGMAFAST | Sigma-Aldrich | S8820 | |
Rocking Shaker | Kasvi | 19010005 | |
SDS-PAGE system | BioRad | 165-8004 | |
Solution Homogenizer | Phoenix Luferco | AP-22 | |
Trizma base | Sigma-Aldrich | T6066-500G | |
Trypsine (TrypLe Express) | Gibco | 12605-028 | |
Western Blotting Luminol Reagent | Santa Cruz Biotechnology | SC-2048 |